Using 18F-FDG PET/CT imaging to detect breast cancer metastases
Official title: Improving Breast Cancer Staging With 18F-FDG PET/CT Imaging (The IMBRECAS PET Study)
Run by Vestre Viken Hospital Trust · NCT05730608 · Data updated 2026-11-12
This study is testing if a special type of imaging called 18F-FDG PET/CT can help find hidden breast cancer spread in patients with more advanced stages of the disease to see if it can change their treatment plans and improve their outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 300 (estimated) |
| Sponsor | Vestre Viken Hospital Trust Academic / other |
| Locations | 1 site (Drammen) |
| Status | Recruiting |
| Started | February 16, 2023 |
| Main results expected | December 31, 2032 |
| Study ends | December 31, 2032 |
| Registry record updated | May 9, 2024 |
| Trial ID | NCT05730608 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women over 18 years old with high-risk primary or recurrent breast cancer who are not currently receiving treatment for other cancers.
✕Probably not a fit
Patients who are male, under 18 years old, pregnant, or have poor general health (ECOG status 3 or higher) may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness of 18F-FDG PET/CT imaging in identifying metastases in patients with stage II/III and locoregional recurrent breast cancer that may not be visible through conventional imaging methods like CT and bone scintigraphy. The primary objective is to determine if the use of this advanced imaging technique can lead to changes in disease staging and treatment decisions. Additionally, the study aims to assess overall survival and progression-free survival in patients whose staging is altered based on the PET/CT findings compared to those whose staging remains unchanged.
Why it matters
Potential benefit: If successful, this study could improve treatment decisions and outcomes for patients with advanced breast cancer by providing more accurate staging information.
How similar studies have gone: Other studies have shown promising results with advanced imaging techniques in cancer detection, suggesting potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with high risk primary or recurrent breast cancer * Non pregnant women \> 18 years * Not receiving active treatment of other cancer types. * Eastern Cooperative Oncology Group (ECOG) status 0-2. Exclusion Criteria: * Pregnant woman * Males * Age under 18 * Patients receiving active treatment for other cancers * Poor general conditipon (ECOG 3 or higher)
Where it's running
-
Drammen Hospital - Vestre Viken HF
Drammen, Norway Recruiting
Study contacts
- Principal investigator: Harald Grut, MD, PHD — Vestre Viken Hospital Trust
- Study coordinator: Harald Grut, MD, PHD
- Email: harald.grut@gmail.com
- Phone: 004797108503
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Oncoliq blood test for early detection of breast cancer
This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
Negative pressure wound therapy after mastectomy
This study tests whether a negative pressure dressing after mastectomy reduces fluid build‑up and common wound complications in women with breast cancer.
-
ATUSA 3D automated breast ultrasound for suspicious breast lesions
This study will test whether the ATUSA 3D automated breast ultrasound system can produce high-quality images that match biopsy results in women with BI-RADS 4 or 5 breast findings.
-
Support tool for women with HR+ breast cancer on long-term endocrine therapy
This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.
-
Conformal ablative radiotherapy for older women with localized ER-positive, HER2-negative breast cancer choosing non-surgical care
This study will test whether five focused SABR treatments can control ER-positive, HER2-negative breast tumors up to 5 cm in women aged 65 and older who are opting for non-surgical management.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.